Cardio-Oncology Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEuropean Georges Pompidou Hospital
About this trial
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias.
CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt.
The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
referred to cardio-oncology
Disqualifiers
refusal to participate
Trial population
All prosepctive patients seen in the cardio-oncology clinic. Observational data will be collected from the medical records. Outcomes measures according to scheduled follow-up visits for their cardiovascular health.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No interventions are planned
Other interventionNon applicable
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Incidence of cardio-toxicty
Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic
Time frame
5 yearsSecondary outcomes
1
Analysis of cardiotoxicity
Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes.
Time frame
5 years2
Analysis of cardioprotective strategies
Correlation between the use of cardiovascular drugs and the number of patients with cardiotoxicity.
Time frame
5 years3
Analysis of underlying cardiovacsular profile
Correlation between underlying cardioascular profile and the number of patients with cardiotoxicity.
Time frame
5 years4
Analysis of arrhythmias
Correlation between incident arrhythmias and cancer drugs
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov